CVRX vs LIVN
CVRX: CVRx commercializes Barostim, the first FDA-approved neuromodulation device that activates baroreceptors to treat severe heart failure in patients who fail traditional medications. LIVN: LivaNova is a medical technology company specializing in innovative cardiovascular and neuromodulation therapies to improve patient lives.
Side-by-side fundamentals
| Metric | CVRX | LIVN | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $5.09 | $78.27 | |
| Market cap as of 2026-07-23 | $135M | $4.3B | |
| P/E as of 2026-07-23 | n/a | 40.32 | |
| PEG as of 2026-07-23 | n/a | 3.92 | |
| Net margin as of 2026-07-23 | -89.2% | +7.5% | LIVN higher |
| Gross margin as of 2026-07-23 | +86.2% | +67.5% | CVRX higher |
| Operating margin as of 2026-07-23 | -84.6% | +13.1% | LIVN higher |
| ROE as of 2026-07-23 | -120.8% | +9.1% | LIVN higher |
| ROA as of 2026-07-23 | -48.4% | +4.2% | LIVN higher |
| Debt / equity as of 2026-07-23 | 2.01 | 0.24 | LIVN lower |
| Revenue growth (YoY) as of 2026-07-23 | +11.7% | +12.4% | LIVN higher |
| Revenue CAGR (3y) SEC XBRL | +36.1% | +10.8% | CVRX higher |
| Beta as of 2026-07-23 | 0.80 | 0.88 | |
| 1-year return as of 2026-07-22 close | -40.0% | +79.7% | LIVN higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.